Literature DB >> 22784382

(18)F-Labeled phosphopeptide-cell-penetrating peptide dimers with enhanced cell uptake properties in human cancer cells.

Susan Richter1, Vincent Bouvet, Melinda Wuest, Ralf Bergmann, Joerg Steinbach, Jens Pietzsch, Ines Neundorf, Frank Wuest.   

Abstract

INTRODUCTION: Phosphopeptides represent interesting compounds to study and elucidate cellular protein phosphorylation/dephosphorylation processes underlying various signal transduction pathways. However, studies of phosphopeptide action in cells are severely constrained by the negatively charged phosphate moiety of the phosphopeptide resulting in poor transport through the cell membrane. The following study describes the synthesis and radiopharmacological evaluation of two (18)F-labeled phosphopeptide-cell-penetrating peptide dimers. The polo-like kinase-1-binding hexaphosphopeptide H-Met-Gln-Ser-pThr-Pro-Leu-OH was coupled to cell-penetrating peptides (CPPs), either sC18, a cathelicidin-derived peptide, or the human calcitonin derivative hCT(18-32)-k7.
METHODS: Radiolabeling was accomplished with the prosthetic group N-succinimidyl 4-[(18)F]fluorobenzoate ([(18)F]SFB) using both, conventional and microfluidic-based bioconjugation of [(18)F]SFB to N-terminal end of phosphopeptide part of the peptide dimers. Cellular uptake studies in human cancer cell lines HT-29 and FaDu cells at 4 °C and 37 °C and small animal PET in BALB/c mice were utilized for radiopharmacological characterization.
RESULTS: Isolated radiochemical yields ranged from 2% to 4% for conventional bioconjugation with [(18)F]SFB. Significantly improved isolated radiochemical yields of up to 26% were achieved using microfluidic technology. Cellular uptake studies of radiolabeled phosphopeptide and phosphopeptide-CPP dimers indicate enhanced internalization of 50% ID/mg protein after 2 h for both phosphopeptide dimers compared to the phosphopeptide alone (<1% ID/mg protein). In vivo biodistribution of (18)F-labeled peptide dimers was determined with small animal PET revealing a superior biodistribution pattern of sC18-containing peptide dimer MQSpTPL-sC18 [(18)F]4.
CONCLUSION: ([18)F]SFB labeling of the phosphopeptide-CPP dimers using a microfluidic system leads to an improved chemoselectivity towards the N-terminal NH(2) group compared to the conventional labeling approach. Cell-penetrating peptide sC18 can be considered as an ideal molecular shuttle for intracellular delivery of the Plk1-PBD-binding hexaphosphopeptide as demonstrated by its favourable radiopharmacological profile.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22784382     DOI: 10.1016/j.nucmedbio.2012.06.003

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  5 in total

Review 1.  The Current Role of Microfluidics in Radiofluorination Chemistry.

Authors:  Karla-Anne Knapp; Michael L Nickels; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

2.  18F-glutathione conjugate as a PET tracer for imaging tumors that overexpress L-PGDS enzyme.

Authors:  Ho-Lien Huang; Ying-Cheng Huang; Wei-Yuan Lee; Chun-Nan Yeh; Kun-Ju Lin; Chung-Shan Yu
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

3.  Characterization of a Cell-Penetrating Peptide with Potential Anticancer Activity.

Authors:  Anja Gronewold; Mareike Horn; Ivan Ranđelović; József Tóvári; Sergio Muñoz Vázquez; Klaus Schomäcker; Ines Neundorf
Journal:  ChemMedChem       Date:  2016-11-18       Impact factor: 3.466

4.  Design and biological characterization of novel cell-penetrating peptides preferentially targeting cell nuclei and subnuclear regions.

Authors:  Anja Gronewold; Mareike Horn; Ines Neundorf
Journal:  Beilstein J Org Chem       Date:  2018-06-07       Impact factor: 2.883

Review 5.  Microfluidics for synthesis of peptide-based PET tracers.

Authors:  Yang Liu; Mei Tian; Hong Zhang
Journal:  Biomed Res Int       Date:  2013-10-31       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.